TABLE 3.
Rate of clinically significant events in patients of different stages of CKD.
| Outcome of rivaroxaban treatment | Rivaroxaban 15 mg daily | Rivaroxaban 20 mg daily | p value | Overall | |
|---|---|---|---|---|---|
| Total recurrent ischemic events (%) | Stage 1 CKD | — | 0 (0) | — | 0 (0) |
| Stage 2 CKD | 1 (11.1) | 2 (4.6) | — | 3 (3.3) | |
| Stage 3 CKD | 1 (6.7) | 1 (7.1) | — | 2 (2.2) | |
| Overall | 2 (8.3) | 3 (4.4) | 0.603 | 5 (5.4) | |
| Stroke/Transient ischemic attack (%) | Stage 1 CKD | — | 0 (0) | — | 0 (0) |
| Stage 2 CKD | 1 (11.1) | 1 (2.3) | — | 2 (2.2) | |
| Stage 3 CKD | 1 (6.7) | 1 (7.1) | — | 2 (2.2) | |
| Overall | 2 (8.3) | 2 (2.9) | — | 4 (4.3) | |
| Deep vein thrombosis (%) | Stage 1 CKD | 0 (0) | — | 0 (0) | |
| Stage 2 CKD | 0 (0) | 1 (2.3) | — | 1 (1.1) | |
| Stage 3 CKD | 0 (0) | 0 (0) | — | 0 (0) | |
| Overall | 0 (0) | 1 (1.5) | — | 1 (1.1) | |
| Bleeding complications (%) | Stage 1 CKD | 0 (0) | 1 (10) | — | 1 (10) |
| Stage 2 CKD | 3 (33.3) | 15 (34.1) | — | 18 (34.0) | |
| Stage 3 CKD | 5 (33.3) | 3 (21.5) | — | 8 (27.6) | |
| Overall | 8 (33.3) | 19 (27.9) | 0.482 | 27 (29.3) | |
| Major Bleeding n (%) | Stage 1 CKD | 0 (0) | 0 (0) | — | 0 (0) |
| Stage 2 CKD | 1 (11.1) | 4 (9.1) | — | 5 (9.4) | |
| Stage 3 CKD | 1 (6.7) | 1 (7.1) | — | 2 (6.9) | |
| Minor Bleeding n (%) | Stage 1 CKD | 0 (0) | 1 (10) | — | 1 (10) |
| Stage 2 CKD | 2 (22.2) | 11 (25) | — | 13 (24.5) | |
| Stage 3 CKD | 4 (26.7) | 2 (14.3) | — | 6 (20.7) | |